BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 35252444)

  • 1. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer.
    Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W
    Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifies microtubule-binding protein
    Wang W; Zhang J; Wang Y; Xu Y; Zhang S
    Comput Struct Biotechnol J; 2022; 20():3322-3335. PubMed ID: 35832625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-Cancer Analysis Revealed
    Liu J; Wang Y; Yin J; Yang Y; Geng R; Zhong Z; Ni S; Liu W; Du M; Yu H; Bai J
    J Oncol; 2022; 2022():3477148. PubMed ID: 35069733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
    Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
    Front Oncol; 2022; 12():927988. PubMed ID: 35756681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pan-cancer analysis of ubiquitin-specific protease 7 and its expression changes in the carcinogenesis of scar ulcer].
    Zhang SY; Ruan JJ; Jin DM; Chen N; Xie WG; Ruan QF
    Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi; 2023 Jun; 39(6):518-526. PubMed ID: 37805766
    [No Abstract]   [Full Text] [Related]  

  • 8. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
    Zhang J; Wang K; Hainisayimu T; Li H
    Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of CD47 in tumor immunity: a potential target for combination therapy.
    Huang J; Liu F; Li C; Liang X; Li C; Liu Y; Yi Z; Zhang L; Fu S; Zeng Y
    Sci Rep; 2022 Jun; 12(1):9803. PubMed ID: 35697717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.
    Wu Y; Huang W; Xie Y; Wang C; Luo N; Chen Y; Wang L; Cheng Z; Gao Z; Liu S
    Front Mol Biosci; 2022; 9():743515. PubMed ID: 35372497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity.
    Liu T; Yang K; Chen J; Qi L; Zhou X; Wang P
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value and immunological role of PDCD1 gene in pan-cancer.
    Miao Y; Wang J; Li Q; Quan W; Wang Y; Li C; Wu J; Mi D
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107080. PubMed ID: 33069926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
    Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
    Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analysis of zinc and ring finger 3 in prognostic value and pan-cancer immunity.
    Liu M; Zhao H; Peng S; Wu Y; Liu Y; Sun W; Zen K; Sun X
    FASEB J; 2024 Mar; 38(5):e23523. PubMed ID: 38457275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RecQ mediated genome instability 2 (
    Wei W; Ying X; Chen L; Sun Q; Lu X; Xia Y; Xu R; Zhu Z; Zhang D; Tang Q; Li L; Xie J; Yu H
    Aging (Albany NY); 2022 May; 14(9):4107-4136. PubMed ID: 35552266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker.
    Yang W; Liu Z; Liu T
    Cell Signal; 2024 May; 117():111107. PubMed ID: 38369265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pan-cancer analysis revealing the role of TIGIT in tumor microenvironment.
    Wen J; Mao X; Cheng Q; Liu Z; Liu F
    Sci Rep; 2021 Nov; 11(1):22502. PubMed ID: 34795387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyroptosis relates to tumor microenvironment remodeling and prognosis: A pan-cancer perspective.
    Khan M; Ai M; Du K; Song J; Wang B; Lin J; Ren A; Chen C; Huang Z; Qiu W; Zhang J; Tian Y; Yuan Y
    Front Immunol; 2022; 13():1062225. PubMed ID: 36605187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-Cancer Analysis Based on
    Zhang Y; Wang S; Han S; Feng Y
    Front Oncol; 2022; 12():844794. PubMed ID: 35359375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.
    Li Y; Han S; Wu B; Zhong C; Shi Y; Lv C; Fu L; Zhang Y; Lang Q; Liang Z; Yu Y; Tian Y
    Front Immunol; 2022; 13():951247. PubMed ID: 35935945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.